JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265313

Human TREX1 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TREX1 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 2 and Insertion of the selection cassette in exon 2.

View Alternative Names

3' 5' exonuclease TREX1, 3' repair exonuclease 1, AGS1, AGS5, CRV, DKFZp434J0310, DNase III, DRN3, Deoxyribonuclease III, dnaQ/mutD (E. coli) like, HERNS, Three prime repair exonuclease 1

3 Images
Sanger Sequencing - Human TREX1 knockout HeLa cell line (AB265313)
  • Sanger seq

Unknown

Sanger Sequencing - Human TREX1 knockout HeLa cell line (AB265313)

Allele-3 : Insertion of the selection cassette in exon 2.

Sanger Sequencing - Human TREX1 knockout HeLa cell line (AB265313)
  • Sanger seq

Unknown

Sanger Sequencing - Human TREX1 knockout HeLa cell line (AB265313)

Allele-1 : 10 bp deletion in exon 2.

Sanger Sequencing - Human TREX1 knockout HeLa cell line (AB265313)
  • Sanger seq

Unknown

Sanger Sequencing - Human TREX1 knockout HeLa cell line (AB265313)

Allele-2 : Insertion of the selection cassette in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 2 and Insertion of the selection cassette in exon 2

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265313-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265313 Human TREX1 knockout HeLa cell line", "number":"AB265313-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265313-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265313 Human TREX1 knockout HeLa cell line", "number":"AB265313-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TREX1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TREX1 also known as Three Prime Repair Exonuclease 1 acts as a DNA exonuclease which degrades single-stranded DNA from the 3' end. This protein exhibits a mass of 33 kDa. TREX1's expression is largely found in the cytoplasm of many cell types including those in the immune system and various tissues like the liver spleen and heart. Through its enzymatic activity TREX1 helps maintain genomic stability by processing DNA intermediates that arise from incomplete DNA replication or repair processes.
Biological function summary

TREX1 removes excessive DNA that might trigger immune responses. It is not a part of a large protein complex but works closely with substrates involved in DNA repair and replication. By degrading abnormal DNA TREX1 prevents the initiation of inappropriate immune responses that could result in autoimmunity. Its functionality is essential in preventing the cell from converting these DNA fragments into ligands for DNA sensors which could activate immune signaling pathways.

Pathways

TREX1 plays a significant role in the DNA damage response and innate immune pathways. In the DNA damage response pathway TREX1 functions alongside proteins like ATR and ATM which address DNA replication stress and repair. Within the innate immune pathway it interacts with cGAS (cyclic GMP-AMP synthase) which can become activated in response to cytosolic DNA leading to the production of type I interferons - powerful immune modulators.

Mutations in TREX1 have been linked to autoimmune diseases such as Aicardi-Goutières syndrome and systemic lupus erythematosus. In these conditions the altered or deficient TREX1 leads to the accumulation of DNA in the cytoplasm falsely triggering an antiviral immune response. This relationship with cGAS is critical as the cGAS-STING pathway becomes activated due to the presence of unprocessed DNA resulting in chronic inflammation and contributing to the autoimmune pathology observed in these disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com